title: Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy.
abstract: Doxorubicin, either as a single agent or in combination regimens, is considered to be one of the most active chemotherapeutic agents in the treatment of metastatic breast cancer. However, its clinical utility is limited by a cumulative, dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure. Considerable research has gone into improving the therapeutic index of doxorubicin-based regimens. A new liposomal formulation of doxorubicin (Myocet, Elan Pharmaceuticals) has a significantly improved therapeutic index compared with conventional doxorubicin. The development of Myocet, a less cardiotoxic, better tolerated and equally efficacious doxorubicin, extends the therapeutic options in the overall management of breast cancer.
authors.affiliation: Jewish General Hospital, McGill University, 3755 Cote St Catherine, Montreal, PQ, H3T 1E2 Canada. gbatist@onc.jgh.mcgill.ca
authors.forename: Gerald
authors.initials: G
authors.lastname: Batist
authors.forename: Jeremy
authors.initials: J
authors.lastname: Barton
authors.forename: Philip
authors.initials: P
authors.lastname: Chaikin
authors.forename: Christine
authors.initials: C
authors.lastname: Swenson
authors.forename: Lauri
authors.initials: L
authors.lastname: Welles
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008081:Liposomes
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D004317:Doxorubicin